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Background: Injecting drug users (IDUs) are at risk of premature mortality. This study examined gender differences
in mortality, risk factors, and causes of death among IDUs.
Methods: In a 13-year cohort study including 172 street-recruited IDUs from Oslo, Norway in 1997, interview data
was merged with the National Cause of Death Registry. Crude mortality rate (CMR) and indirect standardized
mortality ratio (SMR) were estimated with 95% confidence intervals (CI). A log-logistic multivariate survival analysis
model was estimated for the full sample. For a smaller data set (1.1.1998-31.12.2004) the influence of substitution
treatment and prison were assessed using cox regression survival analysis.
Results: Eight females and 37 males died. Acute intoxications were the most common cause of death. Women
were more at risk in the short-term, but more protected in the long-term. CMR was 16.0 [95% CI 8.0, 31.9] for
women and 26.0 [95% CI 18.0, 35.8]) for men. SMR was 39.4 [95% CI 0.2, 220.8]) for women and 21.3 [95% CI 5.7,
54.1] for men. More women injected heroin (98% vs. 88% [x2 = 3.5, p = 0.063]), used prescription drugs (73% vs. 52%
[x2 = 5.6, p = 0.018]) and combined these to inject (45% vs. 26% [x2 = 5.9, p = 0.015]). Mixing prescription drugs in
heroin injections, and sex work (only women) were associated with decreased survival time. There were no gender
differences in access to substitution treatment, while significantly more men had been in prison (74% vs. 51%
[x2 = 7.5, p = 0.006]). The instance of substitution treatment and prison significantly decreased the mortality risk.
Prison release increased the risk, but not statistically significantly.
Conclusions: There were gender differences in mortality and risk factors; sex work and prison were gender specific
risk factors. These factors should be investigated further to better design future preventive measures.
Keywords: Drug user, Injecting drug user, Needle exchange programmes, Overdose, Mortality, Cohort study,
Data linkageBackground
Drug users have a risk of premature mortality 10 to 20
times higher than the general population [1]. Fatal over-
dose is the most common cause of death among drug
users [2-4]. However, this population also has an elevated
risk of death from suicide, violence, transport accidents
and hepatitis C-related causes [5-7]. This suggests that
they are exposed to a wide range of risk factors. These risk
factors differ between men and women [8-10]. A better* Correspondence: lg@sirus.no
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icle, unless otherwise stated.understanding of these differences could provide new in-
sights into how deaths may be prevented.
The risk of premature mortality is higher among male
injecting drug users (IDUs) than females [8-10]. Garrick
and colleagues [11] found a male to female ratio of five
to one in heroin-related deaths. Gossop and colleagues [12]
found a ratio of three men to one woman in a cohort study,
yet when number of deaths was assessed at follow-up they
found a ratio of seven men to one woman. Many studies re-
port a higher crude mortality rate (CMR) for male IDUs
compared to female IDUs [13-15], and the majority of these
studies also find that women have a higher standardized
mortality ratio (SMR) than men [16-18]. The interpretatione BioMed Central Ltd. This is an Open Access article distributed under the terms
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this art-
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this paper. The gender difference in SMR reflects the gen-
der differences in mortality of the general population.
Despite the higher risk of mortality among male IDUs,
some risk factors seem more unique to women. Female
IDUs appear to use and inject drugs as frequently or more
than men [19-23]. Additionally, women are more likely to
engage in sex-work than men [24-27], which has been
associated with premature mortality [27]. Possibly the
pattern of substance use by females, in addition to their
engagement in sex-work increases their risk of mortality.
On the other hand, female drug users are found to seek
treatment earlier in their drug career and they are less likely
to relapse [28,29]. Homelessness and shelter use have been
associated with increased mortality risk [30-32], and there
are more men than women in this population [31,33,34].
Moreover, the first weeks after prison release are associated
with increased mortality risk [35-37]. Women are less likely
to be incarcerated [24,25,37], and less likely to re-offend
[38,39].
Thus, there appears to be some risk factors specific to
women but not to men, and vice versa. The association
of these gender differences with short- and long-term
mortality is assessed in this cohort study of street-recruited
Norwegian IDUs followed from 1997 until 2010. Norway is
a Nordic country with approximately 5 million inhabitants
and the capital Oslo has 600,000 inhabitants [40]. There is
an estimated 8,700 to 12,300 IDUs (predominantly opioids)
and approximately 3,000 of them live in the capital [41].
Since 1997, Norway has had one of the highest rates of
IDUs among problem drug users in Europe [1]. In 1997,
1.5 million syringes were distributed and 103,000 individ-
ual visits were registered in the only needle exchange
programme (NEP) in Oslo. This illustrates the high preva-
lence of injection use in the city.
Furthermore, Norway has one of the highest reported
drug-induced mortality rates in Europe [1]. There are
between 250 and 300 drug-induced deaths annually and
about one-third occurs in Oslo [42]. Oslo is therefore a
suitable setting for an examination of mortality and as-
sociated risk factors. The aim of this study was to assess
gender differences in mortality, risk factors and causes of
death. This study includes an out-of-treatment population
of IDUs whom reported severe risky drug use behaviour at
the time of baseline interview. The study is also likely to in-
clude IDUs who would not have been available for inclusion
in studies where participants were recruited from treatment
or prison settings. The findings may therefore provide new
insights into how these deaths may be prevented.
Methods
Design and study setting
This was a prospective cohort study among street-recruited
IDUs outside the only NEP facility in Oslo in March, Juneand September 1997. This was the only facility where IDUs
could obtain clean injecting equipment for free in Oslo at
the time. The NEP facility was a bus that was situated in
different locations in the city centre throughout the even-
ing. The city centre is fairly small and it was rarely more
than ten minutes walking distance between the different
locations. Therefore subjects were recruited at various
locations in the city centre.
Interview data was merged with the National Cause of
Death Registry between 1997 and 2010 using the subjects’
social security number. Intake and discharge dates for opi-
oid substitution treatment (OST) were obtained from the
OST programme in Oslo between 1.1.1998 and 31.12.2004.
The Norwegian OST programme was established January
1st 1998 [43] and therefore it was not possible to obtain in-
take dates prior to this. Incarceration dates and release
dates between 1.1.1997 and 31.12.2004 were obtained from
Norwegian Correctional Services.
Participants, recruitment and interviews
Participants were recruited outside the NEP facility after
they had collected injecting equipment. Researchers and
trained research assistants from The Norwegian Institute
for Alcohol and Drug Research recruited and interviewed
the participants. The researchers and trained research as-
sistants were situated on the street outside the NEP and
they operated separately from the facility. This means that
NEP staff were informed that the study was conducted
outside their bus, but they were not involved in the re-
cruitment process nor in any other aspect of the study.
The inclusion criterion was for people to have injected
at least once in the previous four weeks. Each interview
took approximately 15 minutes to complete and was con-
ducted out of earshot from others. No monetary incen-
tives were given for participation.
Representativeness
The NEP facility was the primary source for clean needle
and syringes in 1997. This means that most IDUs in
Oslo would have been likely to visit the facility at some
time during the year. The data was collected three times
over the year (March, June and September) which increased
the likelihood of obtaining a representative sample. Further-
more, the gender and age distribution of our sample was
similar to what was recorded for IDUs in Norway at the
time [44]. People who inject drugs regularly are more likely
to attend the NEP than those who inject less frequently.
Consequently our sample probably included a higher pro-
portion of the former population than the latter.
We have no information about those who refused to
participate in the baseline interview. However, from the
286 subjects who were invited to participate, 172 agreed
to participate in the long-term follow up study by provid-
ing their name and social security number. Those who did
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tionnaire anonymously. Those who agreed to participate
did not differ from those who did not (n = 114). Both
groups had a similar distribution in terms of age, gender,
education, age at first injection, income, amount of heroin
per injection and total amount of heroin consumed [45].
Measures
The study questionnaire comprised detailed questions
about age, gender, education, current living situation, and
sources of income (work, social benefits, dealing, theft and
sex work) and amount of income from each income source.
In this study dealing and theft were defined as illegal activ-
ities. The questionnaire also included questions about
alcohol; the amount and frequency of cannabis use; the
frequency of cocaine, LSD and ecstasy use. In addition,
the respondents were asked if they had used heroin and if
they had, their mode of intake (by injections, inhalation or
smoking) and the amount of heroin in their last injection
(if they had injected). The respondents were also asked
about the age of their first injection, injection frequency
and what substance they most commonly injected: heroin,
amphetamine, both or other substances.
Furthermore, the questionnaire comprised questions
about prescription drugs (frequency, type of drug and
amount). In 1997, methadone and buprenorphine were not
available as prescription drugs in Norway. Instead prescrip-
tion drugs such as pain medication, sedatives, hypnotics
and antiepileptic drugs were available. The respondents
were also asked if they mixed prescription drugs and her-
oin and if they did, how often and what quantity of pre-
scription drugs were used. The questionnaire is described
in more detail elsewhere [45].
The National Cause of Death Registry provided the dates
of death and the primary causes of death of the participants.
Causes of death were categorized by Statistics Norway ac-
cording to the international classification system (ICD-9
codes). We divided the primary causes of death into six
categories. The first category was acute intoxications
with three subcategories “due to use of opioids (F11.0)”,
“due to use of sedatives or hypnotics (F13.0)” and “Acciden-
tal poisoning by and exposure to narcotics and psychody-
sleptics [hallucinogens], not elsewhere classified (X42.0)”.
The other categories were dependence syndrome (F11.2,
F19.2), suicide (X70.0, X71.9), acute infections (A39.8,
A41.9), chronic infections (B18.2, B20.7, B24.0), and other
causes (C49.6, J45.9, K70.3, R99.8, V48.6, W74.8, X59.9
X99.8, Y21.8).
The OST programme in Oslo provided intake and dis-
charge data, and The Norwegian Correctional Services
provided incarceration dates and release dates. The infor-
mation from the OST programme and The Norwegian
Correctional Services were used in sub-analyses in a smaller
dataset.Data linkage
Staff at the Norwegian Social Science Data Services per-
formed linkage of data using mortality data from The
National Cause of Death Registry and OST dates for in-
take, discharge, incarceration and release. The social secur-
ity number was used for matching purposes. A linked data
set was then provided to the researchers.
Variables and data analyses
Data analyses were completed using Stata version 13.0
[46]. Chi square tests were used for the assessment of
differences in baseline characteristics between genders. The
cut-off points for the dummy variables “age” and “length
of injection career” were based upon Darke and colleagues
paper from 2011 [3]. The cut-off point for “Total monthly
income” was the median value for the total sample which
was 33,000 Norwegian Kroner (NKR). This was approxi-
mately 3,560 Great British Pounds (GBP). The cut-off
for the total monthly amount of heroin was the median
amount of heroin used by the total sample (12.9 grams).
Crude mortality rate (CMR) was calculated by summing
the person years (PY) contributed by each participant, by
gender and calendar year, then summing the number of
deaths by the same groups and calculating a rate per 1000
PY. Indirect standardized mortality ratio (SMR) was calcu-
lated by dividing the observed deaths in the cohort by the
expected deaths if the cohort had the same specific rates
as the death rate in the standard population. The standard
population was the general population in Norway between
1997 and 2010 based on age and gender specific rates
[40]. The SMR was calculated using the age groups 15–
19, 20–24, 25–29, 30–34, 35–39, 40–44, 45–49 and 50–54
years. All rates and ratios were reported with 95% Confi-
dence Intervals (CI).
Two types of survival analyses were conducted. In the
first analyses, time-at-risk was the period between the
date of baseline interview (interviews conducted March,
June or September 1997) and December 31st 2010. A con-
tinuous time model could thus be used. Incomplete spells
were right-censored. The proportionality assumption for
gender was not satisfied and therefore a proportional haz-
ard model such as a Cox regression model could not be
used. An Accelerated Failure Time (AFT) parametric model
was used instead.
AFT models use log (time-to-failure), rather than risk
(hazard) of failure [47]. The regression coefficient B*k in
AFT models summarizes the proportional effect on survival
time T to a unit change in the corresponding covariate [47].
However, it is more common to present the exponentiated
regression coefficients, which are called time ratios (TR)
[47]. Therefore, this paper reports TR for each covariate’s
estimates. TR ranges between 0 and infinity and a coeffi-
cient above 1 implies longer duration of survival, while
a coefficient below 1 implies shorter duration [47]. For
Gjersing and Bretteville-Jensen BMC Public Health 2014, 14:440 Page 4 of 11
http://www.biomedcentral.com/1471-2458/14/440example, if TR for men in a mortality study is three, it
means that men have three times longer survival then
women. On the other hand if TR for men is 0.3, then
men have 70% shorter survival then women.
The three AFT models “Log-Logistic”, “Log-Normal”
and “Weibull AFT” were assessed [47]. The Log-Logistic
model was chosen based upon an assessment of the AIC
criterion and Log-Likelihood estimates.
Unobserved heterogeneity (“frailty”) was controlled for
by estimating the models using a Gamma specification
[47]. To check robustness, the same assessment was con-
ducted with Log-Normal and Weibull AFT models.
The multivariate Log-Logistic model was theoretically
based and we used known risk factors for increased mor-
tality among drug users. These factors were age, sex work,
length of injecting career, injection frequency, combination
of heroin and prescription drugs in injections and alcohol
use [9,12,13,17,18,27,48-50].
Almost all participants (90%) had injected daily or al-
most daily and therefore there was not enough variation
in frequency of use to include this variable in the regres-
sion analyses. Since we adjusted for the combination of
prescription drugs in heroin injections, we could not use
“Any use of prescription drugs” or “heroin use” as separate
variables.
There were no reports of income from sex work from
men, while 21 of the 44 women did. Therefore sex work
was only included as an independent variable in Model 3,
where females were analysed separately from males. In
model 4, males were analysed separately, excluding sex
work from the model. It was not possible to control for
frailty in model 3 and 4, which was most likely due to a
small sample size.
In the second survival analysis, time-at-risk was the
period between 1.1.1998 and 31.12.2004. “Total years in
OST” was used as the variable for substitution treatment.
“Total years in prison” was used as the variable for incar-
ceration. “Prison release” was included in the model as
a time-dependent covariate. Since data on imprison-
ment and prison release was available from 1.1.1997, data
was left censored (imprisonment dates before 1.1.1998
were omitted from the analyses). Incomplete spells from
31.12.2004 were right censored. Data had to be split into
incarceration episodes. Due to the organisation of data, it
was not possible to use the Log-Logistic model. However,
in this limited time model the proportionality assump-
tion was satisfied also for gender. The proportionality
assumptions were tested using Schoenfeld residuals, and
scaled Schoenfeld residuals [51]. A Cox regression survival
model could therefore be applied and hazard ratios (HR)
and 95% CI were reported.
Four models were assessed. Model 1 comprised of “total
years in OST”, “total years in prison” and “prison release”,
to measure the effect on mortality without the othervariables. “Prison release” was the risk up until three
weeks after release. In model 2, the original variables were
added to the analyses. In model 3, women were analysed
separately and in model 4, men were analysed separately.
It was not possible to assess for unshared frailty (unob-
served heterogeneity) in Cox regression analyses [52] and
consequently this was not assessed.
The differences in baseline characteristics between the
women who reported income from sex work and those
who did not, were assessed in post-hoc analysis. The rea-
son for the post-hoc analysis was that sex work signifi-
cantly decreased survival time in the Log-Logistic analyses
and we wanted to determine possible reasons for this. One
hypothesis was that high income from sex work allowed
these women to consume more drugs and thereby short-
ening their survival time. To explore this further, we com-
pared the women who reported income from sex work to
women who did not. Fisher’s Exact Test was used. For the
continuous variables of “total monthly income”, “number
of prescription drugs used yesterday”, “amount of heroin
per injection”, “number of days used heroin in the past
month” and “total amount of heroin used in the past
month” a two-sample t-test with equal variances was used.
For all analyses, the significance level was set at 5%
level, unless otherwise stated in the text.
Ethics
This study was approved by the Norwegian Medical
Ethics committee, the Norwegian Data Inspectorate and
the Norwegian Board of Health Supervision.
Results
Characteristics of the cohort
Our cohort of 172 IDUs, was made up of 44 women and
128 men. The mean age at the baseline interview was
32.5 years (sd 7.1). Women were on average five years
younger than the males (28.9 vs. 33.7). Table 1 shows that
there were no gender differences in educational attain-
ment, but there were significant gender differences in
sources of income. Only 2% of the 44 women reported
income from work compared to 20% of the 128 men
(x2 = 7.6, p = 0.006). In comparison, 48% of the women
reported sex work as an income source, whereas no men
reported this as an income source (x2 = 69.6, p < 0.001).
More women than men reported a total monthly income
above the median monthly income in the total sample
which was 33,000 NKR (61% vs. 45% x2 = 3.7 p = 0.054).
Table 1 also shows that the majority of participants
(91%) had injected mainly heroin rather than amphetamine
and other opioids, in the four weeks prior to inclusion. A
higher proportion of the women injected mainly heroin
compared to the men (98% vs. 88% x2 = 3.5, p = 0.063). Yet
there were no significant gender differences in those who
had used more heroin than the median amount used by





n = 44 (100%) n = 128 (100%) n = 172
Age groups
≥ 30 years 22 (50%) 85 (66%) x2 = 3.8 p = 0.053* 107 (62%)
> Mandatory years of educationa
Yes 29 (66%) 94 (73%) x2 = 0.9 p = 0.340 123 (72%)
Work income
Yes 1 (2%) 25 (20%) x2 = 7.6 p = 0.006** 26 (15%)
Sex work
Yes 21 (48%) 0 x2 = 69.6 p < 0.001*** 21 (12%)
Theft
Yes 15 (34%) 50 (39%) x2 = 0.3 p = 0.557 65 (38%)
Dealing
Yes 14 (32%) 50 (39%) x2 = 0.7 p = 0.391 64 (37%)
Monthly income > 33,000 NKRb
Yes 27 (61%) 57 (45%) x2 = 3.7 p = 0.054* 84 (49%)
Years of injecting career
> 5 years 32 (73%) 105 (82%) x2 = 1.2 p = 0.279 137 (80%)
Drug use in the previous four weeks
Daily or almost daily injections
Yes 42 (95%) 113 (88%) x2 = 1.9 p = 0.169 155 (90%)
Heroin most injected
Yes 43 (98%) 113 (88%) x2 = 3.5 p = 0.063* 156 (91%)
To have injected > 12.9 grams of heroinc
Yes 29 (66%) 67 (52%) x2 = 2.4 p = 0.118 96 (56%)
Combined heroin and prescription drugs in injections
Yes 20 (45%) 33 (26%) x2 = 5.9 p = 0.015** 53 (31%)
Any use of prescription drugs
Yes 32 (73%) 67 (52%) x2 = 5.6 p = 0.018** 99 (58%)
Alcohol ≥2 days a week or more
Yes 10 (23%) 31 (24%) x2 = 0.04 p = 0.841 41 (24%)
Cannabis ≥2 days a week or more
Yes 13 (30%) 52 (41%) x2 = 1.7 p = 0.191 65 (38%)
*p < 0.10, **p < 0.05, ***p < 0.001.
aIn Norway all children are expected by law to attend school for 10 years. Prior to 1997, it was nine years.
bThe cut-off was set at the median total income in Norwegian Kroner in the total sample. In 2013 33,000 NKR amounts to 3,560 GBP.
cThe cut-off was set at the median amount of heroin injected by the total sample which was 12.9 grams of heroin injected in the past month.
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combined prescription drugs in heroin injections (45% vs.
26% x2 = 5.9, p = 0.015). Further, more women used pre-
scription drugs in the month previous to the study, than
men (73% vs. 52% x2 = 5.6, p = 0.018).
Mortality and assessment of risk factors
The cohort was followed for a total of 1,927 PY. By 2010,
45 participants died; 8 females and 37 males. Women had
a lower CMR than the men (16.0 [95% CI 8.0, 31.9] vs.26.0 [95% CI 18.0, 35.8]), but these differences were not
statistically significant. Conversely, men had a lower SMR
than the women (21.3 [95% CI 5.7, 54.1] vs. 39.4 [95% CI
0.2, 220.8]).
The highest number of deaths occurred in the first two
years of follow-up. Eight participants died in the first year
of the study and nine participants died in the second year.
Of those who died, women died on average (median)
1.2 years after the baseline interview and only one female
died after three years. The deceased men died on average
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after three years. Figure 1 shows that men had a higher
hazard function than the women throughout the study
period. However, both men and women had a high hazard
function in the first two years and thereafter a decrease.
The survival function in Figure 1 illustrates that women
had higher probability of survival than men.
Table 2 shows that when survival for men and women
were analysed using both unadjusted and adjusted log
logistic regression there were no significant gender dif-
ferences (Table 2). Survival time significantly decreased
on a 10% significance level (p = 0.055) when participants
had combined heroin and prescription drugs in injections
in the previous four weeks before the interview (TR = 0.4
[95% CI 0.01, 1.0]. When accounting for unobserved het-
erogeneity (Model 2), the estimates remained similar to the
model without (Model 1) and, the likelihood-ratio test was
not statistically significant (x2 = 0 p = 1.000). This means
that unobserved individual effects were negligible in this
model.
Since no men reported sex work as an income source,
it could not be included in the full model. Instead women
were analysed separately. Women who reported income
from sex work had 98% decreased survival time (TR = 0.02
[95% CI 0.0, 1.8]) and this was significant on a 10% signifi-
cant level (p = 0.090).
In the post hoc analysis, we assessed the differences in
baseline characteristics between women who reported in-
come from sex work (n = 21) and those (n = 23) who did
not. There was a higher proportion “older than 30 years”
among those who reported sex work as an income source
(67% vs. 35%, p = 0.069). Fewer of those in sex work re-
ported income from theft (19% vs. 48%, p = 0.060). Those
in sex work reported a higher mean monthly income
(57,600 NKR vs. 38,200 NKR, p = 0.006). Most importantly,
a higher proportion of those in sex work used prescription
drugs in combination with heroin the previous four weeks
(90% vs. 57%, p = 0.017). Additionally, although not sta-













Figure 1 Hazard and survival function* by gender using Log-Logistic
combination of prescription drugs in heroin injections, alcohol use and prosex work had used slightly more prescription drugs in
addition to heroin in the day before the interview (9.4
tablets vs. 6.0 tablets, p = 0.178); slightly more heroin per
injection (0.18 g vs. 0.16 g, p = 0.445); used heroin for
slightly more days in the past month (29.0 days vs. 27.8 days,
p = 0.512); and consequently consumed slightly more her-
oin in total in the past month (23.5 g vs. 21.4 g, p = 0.715).
As described in the Methods section, information on
substitution treatment, incarceration and prison release
was only available between 1.1.1998 and 31.12.2004. With
this limited data set the study population was 169, as three
people died before 1.1.1998 (1 female and 2 males). In this
smaller data set there was a significant difference between
the proportion of men and women who had been in
prison during the study period. Of 43 women, 51% had
been in prison compared to 74% of the 126 men (x2 = 7.6,
p = 0.006). On the other hand, there was no significant dif-
ference between the proportion of women and men who
had been in substitution treatment (44% vs. 41% x2 = 0.1,
p = 0.738).
Table 3 shows the effects of OST, incarceration and
prison release on the risk of mortality using cox regres-
sion survival analysis. This table shows that for each
year in OST, the risk of death was reduced by 30% (HR
= 0.7 [95% CI 0.05, 0.9]) and for each year in prison, the
risk was reduced by 90% (HR = 0.1 [95% CI 0.0, 0.6]).
Prison release (<3 weeks) increased the risk of mortal-
ity more than four times (HR = 4.3 [95% CI 0.5, 34.7]),
however this was not significant, not even on a 10% sig-
nificance level (p = 0.169) when also adjusting for co-
variates (HR = 3.4 [95% 0.7, 20.4]). For women, each
year in OST reduced the mortality risk by 99% (HR =
0.1 [95% CI 0.0, 0.6]) and each year in prison reduced
the mortality risk by 97% (HR = 0.03 [95% CI 0.0, 0.7])
also in the adjusted model. In this adjusted model sex
work increased the mortality risk almost twenty-three
times (HR = 22.7 [95% CI 1.5, 33.8]). It was not possible to
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Table 3 Adjusted effects of substitution treatment, incarceration and prison release on risk of mortality assessed using
Cox regression analysis in a limited study period 1.1.1998 and 31.12.2004 (n = 169)ab









Male - 1.7 [0.7, 4.3] - -
≥ 30 yearsc - 0.8 [0.3, 1.9] 1.5 [0.2, 12.1] 0.5 [0.2, 1.3]
> 5 years IV careerc, d - 1.5 [0.5, 4.2] 0.7 [0.0, 13.8] 1.7 [0.5, 5.2]
Heroin and prescription drugse, f - 1.4 [0.7, 3.0] 0.8 [0.1, 4.1] 1.5 [0.6, 3.5]
Alcohol ≥2 days a weekf - 1.1 [0.5, 2.3] 2.6 [0.3, 20.8] 1.1 [0.5, 2.5]
Sex workf - - 22.7 [1.5, 333.8]** -
Total years in OST 0.7 [0.5, 0.9]** 0.7 [0.5, 0.9]** 0.1 [0.0, 0.6]** 0.7 [0.5, 1.0]**
Total years in prison 0.1 [0.0, 0.6]*** 0.1 [0.0, 0.6]*** 0.0 [0.0, 0.7]** 0.1 [0.0, 0.6]**
Prison releasea 4.3 [0.5, 34.7] 3.7 [0.4, 30.3] -g 3.2 [0.6, 16.4]
*p < 0.10, **p < 0.05, ***p < 0.001.
aData was only available from OST from 1.1.1998 when OST was established as a national programme in Norway. The follow-up time for this table is therefore
from 1.1.1998-31.12.2004. Three cases died before 1.1.1998 and therefore had to be omitted; the study population was therefore 169 and not 172 as in the
original sample.
bIt was not possible to run the log logistic regression model due data organization. Please see the Methods section for more detail. However, this model satisfied
the proportionality assumption and therefore a Cox regression survival analysis could be used. In this model HR and 95% CI are reported.
cAt inclusion.
d> 5 years between first injection and interview.
eCombined heroin and prescription drugs in injections.
fIn the previous four weeks before the baseline interview.
gUnable to estimate the effect of prison release on women due to a small sample size.
Table 2 Unadjusted and adjusted time ratio (TR) for survival time using Log-Logistic regression analysis, with and
without unobserved heterogeneity (“frailty”)
Model 1:
total population




Unadjusted Adjusted Adjusted Adjusted Adjusted
TRc [95% CI] TRc [95% CI] TRc [95% CI] TRc [95% CI] TRc [95% CI]
Male 0.5 [0.2, 1.7] 0.5 [0.1, 1.7] 0.5 [0.1, 1.7] -
≥ 30 yearsd 0.8 [0.3, 2.1] 0.8 [0.3, 2.3] 0.8 [0.3, 2.3] 0.1 [0.0, 4.5] 1.3 [0.5, 3.6]
> 5 years IV careere 0.8 [0.2, 2.7] 1.1 [0.3, 3.8] 1.1 [0.3, 3.8] 1.0 [0.0, 152.3] 1.1 [0.3, 3.7]
Combined heroin and prescription drugsf, g 0.4 [0.2, 1.1]* 0.4 [0.1, 1.0]* 0.4 [0.1, 1.0]* 0.2 [0.0, 5.3] 0.5 [0.2, 1.2]
Alcohol ≥2 days a weekg 0.8 [0.3, 2.3] 0.8 [0.3, 2.4] 0.8 [0.3, 2.4] 0.3 [0.0, 11.8] 0.8 [0.3, 2.3]
Sex workg 0.4 [0.1, 1.7] - - 0.02 [0.00, 1.8]* -
n 171 171 171 43 128
Gamma - 1.4 [1.0, 1.8] 1.4 [1.0, 1.8] 1.8 [1.0, 3.4] 1.2 [0.9, 1.6]
Theta - - 0 - -
Log-Likelihood - −161.7 −161.7 −30.7 −125.2
Akaike’s Info. Crit. - 337.5 339.5 75.4 70.7




cTime ratio for covariate k = exp (β*k).
dAt inclusion.
e> 5 years between first injection and interview.
fCombined heroin and prescription drugs in injections.
gIn the previous four weeks before the baseline interview.
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Table 4 shows the causes of death in detail. Of the 45
who died, 60% died from acute intoxications (25 cases)
and dependence syndrome (2 cases). Therefore, acute in-
toxications were the most common cause of death.
Seventeen (5 females and 12 men) of the acute intoxica-
tions were due to the use of opioids. Seven (all men) were
defined as accidental poisoning by and exposure to nar-
cotics and psychodysleptics. One male death was classified
as acute intoxication due to use of sedatives or hypnotics.
The other causes of death are found in Table 4.
Discussion
The risk of mortality was highest in the first two years
after inclusion for both genders. Within the first three
years, 22 of the 172 participants died (13%). The deceased
females died median 1.2 years and males 5.1 years after in-
clusion. This suggests that women were more at risk in the
short-term, but more protected in the long-term. The most
common cause of death was acute intoxications with no
significant gender differences. The risk factors associated
with decreased survival time were combining prescription
drugs in heroin injections and sex work (only women in
this study). In sub-analyses conducted on a smaller data
set, prison release did not significantly increase the mortal-
ity risk, while time in prison significantly decreased the
risk. A significantly higher proportion of men had been in
prison. The same proportion of men and women had been
in OST and the mortality risk was reduced in both genders
while they were in treatment. Therefore, the two gender
specific risk factors found in this study were sex work
and prison.
Women appeared to be more vulnerable in the short-
term as the majority of the women who died, died in the
first three years after inclusion. Women had a more haz-
ardous pattern of substance use in the weeks before study
inclusion. More women had injected heroin and they had
consumed similar amounts of heroin as the males and
with the same frequency. Further, female IDUs consumedTable 4 Primary causes of death of the 45 deaths recorded d
Primary causes of death Wome
Acute intoxications
Due to the use of opioids
Due to use of sedatives or hypnotics
Accidental poisoning by and exposure to narcotics and
psychodysleptics [hallucinogens], not elsewhere classified
Dependence syndrome
Suicide
Acute infections (meningococcal infections and sepsis)
Chronic infections (hepatitis C and HIV)
Other causes (traffic accidents, drowning, asthma,
malignant neoplasm of other connective and soft tissue)more prescription drugs and more frequently combined
prescription drugs with heroin injecting. They also used
alcohol as frequently as the men. Injection frequency, her-
oin injections, use of prescription drugs and alcohol use
are all factors that are known to increase the risk of pre-
mature mortality among drug users [9,13,48]. The pattern
of substance use among the female participants is likely to
be one of the reasons why the majority of the women who
died, died in the first three years after the interview. How-
ever, the combination of prescription drugs in heroin in-
jections was not statistically significant when women were
analysed separately. Possibly in a larger female population
it would have been possible to detect a significant associ-
ation between the pattern of substance use and death.
Despite the few female deaths, sex work was signifi-
cantly associated with survival time on a 10% significance
level and this is similar to the findings from a Canadian
study [27]. It could be that sex work decreased survival
time due to risk of HIV and HIV-related causes of death.
However, none of the women in our study died from HIV-
related causes. Instead, six of the females died from acute
intoxications, one from suicide and one from other causes.
It is not likely that sex work increases the risk of acute
intoxications per se. However, sex work is likely to be an
indicator of hazardous behaviour that directly increases
the risk. There might be unobserved commonalities among
those who reported sex work as an income source, which
in turn are associated with survival time. It was not possible
to assess for heterogeneity when women were analysed sep-
arately due to the small sample size and the question in
regards to unobserved heterogeneity among women there-
fore remains unanswered.
On the other hand, it could be that the high income
from sex work allowed these women to consume more
drugs and thereby shortening their survival time. To ex-
plore this further, the women who reported income from
sex work were compared to women who did not. This ana-
lysis indicated that a higher proportion of those from the
former group had a higher total monthly income and auring follow-up
n n = 8 (100%) Men= 37 (100%) Total n = 45 (100%)
5 (63%) 12 (32%) 17 (38%)
0 1 (3%) 1 (2%)
0 7 (19%) 7 (16%)
1 (12%) 1 (3%) 2 (4%)
1 (12%) 2 (5%) 3 (7%)
0 2 (5%) 2 (4%)
0 4 (11%) 4 (9%)
1 (12%) 8 (22%) 9 (20%)
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The association between sex work and mortality should be
researched further to understand if there is a causal link
between the two.
Combining different substances such as prescription
drugs and heroin is a well-known risk factor for acute
intoxications [13,50,53]. One study found that for every
additional drug used, the odds ratio for mortality almost
doubled [12]. In our study, survival time for those who
combined prescription drugs in heroin injections decreased
by 60%. Based upon previous literature [12,13,50,53] and
the findings from this study, it is likely that combination of
different substances is directly associated with shorter sur-
vival time.
The survival function in Figure 1 shows that women had
a much higher probability of survival than men. Only one
female died after the first three years of follow-up, whereas
23 men died in the same time period. Women were there-
fore more protected in the long-term. One possible reason
for the higher probability of survival could be that female
drug users sought treatment earlier in their drug career
and they were less likely to relapse [28,29,54]. Treatment
reduces the risk of mortality [55-57]. Possibly treatment
was more accessible to women than men during the study
period and thereby increasing females’ probability of sur-
vival. Furthermore, women are less likely to be incarcerated
[24,25,37] and less likely to re-offend [38,39]. It could be
that gender differences in incarceration and treatment in-
creased females’ probability of survival.
To assess the effect of substitution treatment and prison
episodes on the mortality risk, we re-analysed the data
using a smaller data set. As hypothesized, fewer females
had been incarcerated and this could indeed be one rea-
son why more females survived than men. Yet contrary to
our initial hypothesis that release from prison significantly
increased the mortality risk [35,37,58], the estimates in
this study were not significant not even on a 10% sig-
nificance level. Instead, each year in prison significantly
decreased the mortality risk by 30%. This means that to
spend time in prison was protective, while prison release
did not significantly increase the risk. More men, than
women, were incarcerated during the study period. Viewed
in isolation it would seem men were more protected. Yet
overall more men died. This suggests that there must be
other gender specific risk factors not observed in this
study, that increase the risk more for men than for women.
These unobserved gender specific risk factors should be in-
vestigated in future studies to discover how to improve sur-
vival among male drug users.
It was found that time in OST significantly decreased
the risk of death which is in accordance with previous
literature [55-57,59]. A priori we hypothesized that more
females would be in OST compared to males, and thereby
be more protected. Contrary to what was expected it wasthe same proportion of females and males who had been
in OST during the study period (44% vs. 41%). This means
that OST was not a gender specific factor that protected
women due to a higher proportion of women in OST.
However, we did not have information regarding other
types of treatment and it may be that more women than
men, had access to alternative treatment.
The majority of deaths occurred in the first three years
of follow up. A rapid increase of OST patients, in particu-
lar after the year 2000 [43], could possibly be one reason
why there were fewer deaths after three years. On the
other hand, it may also be that those who died in the early
years of follow-up were those who were particularly vul-
nerable, while those who had survived up until three years
after inclusion had characteristics that enhanced survival.
Though we did not explore this in our study. There could
also be other factors not identified in this study that pro-
tected the participants after three years. It is likely that the
reasons why fewer died after three years are due to a com-
bination of the reasons listed above.
Limitations and strengths
One of the study’s limitations is sample size which limits
the statistical analyses in regards to possibilities of findings
statistical significance at a 5% level. Additionally, common
to all studies that use self-reported data, weaknesses of
our study might include selection bias, recall bias, under
and over-reporting, and imprecise estimation of illegal
activities. Although the quality of the National Cause of
Death Registry is deemed reliable for the date of deaths,
the primary cause of deaths, which depends on assess-
ment by individual doctors, is somewhat more vulner-
able for misclassifications [60].
Another limitation was that the respondents were not
asked in detail about amphetamine and other opioid use.
This information would have given a more detailed pic-
ture of the respondents’ substance use at the time of the
interview.
Our study did not include information about those who
refused to participate in the baseline interview and so it is
not known how these people differed from those who par-
ticipated, if at all. However, the gender and age distribu-
tion of our sample was similar to what was observed for
IDUs in Norway at the time [44], which should suggest
that they did not differ. Regardless, this is not known and
the lack of this information may have biased the results in
some manner.
One of the main strengths of our study is that it was
a prospective longitudinal cohort study that followed
the study participants over 13 years. This enabled us to
compare short- and long-term survival between men
and women. Despite the small sample size it was possible
to detect significant differences at a 5% significance level.
We also obtained data from those who refused to
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showed that the participants did not differ from those who
did not participate. This reduced the chances for selection
bias. Finally, participants were street-recruited which was
unique as these people may not be available for inclusion
in treatment or prison-based studies. The reason for this is
that they may never have accessed treatment or been to
prison. This study gives insights into a population that are
currently exposed to the risks factors related to injecting
drug use.
Conclusion
This study found gender differences in mortality and in
the risk factors for premature death, which may be useful
in developing preventive measures. Women were more
vulnerable in the short-term, whilst more protected in the
long-term. One of the gender specific risk factors found
in this study was sex work, associated only with females.
Therefore, female IDUs who use sex work as an income
source should therefore be addressed specifically. It may be
assumed that male IDUs would experience the same level
of risk associated with sex work. However the findings
from our study could not confirm this assumption. Con-
trary to our initial hypothesis, OST was not a gender spe-
cific risk factor. The same proportion of men and women
had been in OST during the study period and the mortality
risk was significantly reduced in both genders whilst they
were in treatment. Prison was a gender specific risk factor,
as a significantly higher proportion of men had been in
prison. Time in prison significantly decreased the mortality
risk, while prison release did not significantly influence the
risk. As such, it was expected that men should be more
protected than women, yet they were not. Therefore there
must be other factors causing an increase in mortality risk
more among men, but these factors were not uncovered in
this study. Improved understanding of these gender differ-
ences could help to reduce the mortality risk in both male
and female IDUs. Finally, the combining of different sub-
stances should be a significant consideration in developing
preventive measures, as this was associated with a shorter
survival time, for both men and women.
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